These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10096712)

  • 1. Removal of pyrogens by filtration?
    Turco SJ
    Am J Health Syst Pharm; 1999 Mar; 56(5):477. PubMed ID: 10096712
    [No Abstract]   [Full Text] [Related]  

  • 2. Visual compatibility of abciximab with selected drugs.
    Baroletti S; Hartman C; Churchill W
    Am J Health Syst Pharm; 2002 Mar; 59(5):466-7. PubMed ID: 11887414
    [No Abstract]   [Full Text] [Related]  

  • 3. Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.
    Patel K; Hursting MJ
    Am J Health Syst Pharm; 2005 Jul; 62(13):1381-4. PubMed ID: 15972381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abciximab vials as multidose containers.
    Yee WP; Norton LL
    Am J Health Syst Pharm; 1998 Oct; 55(19):2026-7. PubMed ID: 9784793
    [No Abstract]   [Full Text] [Related]  

  • 5. Depyrogenation of a parenteral solution by ultrafiltration.
    Abramson D; Butler LD; Chrai S
    J Parenter Sci Technol; 1981; 35(1):3-7. PubMed ID: 7229828
    [No Abstract]   [Full Text] [Related]  

  • 6. Design and operation of an in-house pyrogen test facility.
    Armistead RL; Taylor NL
    Bull Parenter Drug Assoc; 1977; 31(1):14-7. PubMed ID: 831894
    [No Abstract]   [Full Text] [Related]  

  • 7. Depyrogenation by endotoxin removal with positively charged depth filter cartridge.
    Hou KC; Zaniewski R
    J Parenter Sci Technol; 1990; 44(4):204-9. PubMed ID: 2213428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of pyrogens--application of molecular filtration.
    Cradock JC; Guder LA; Francis DL; Morgan SL
    J Pharm Pharmacol; 1978 Mar; 30(3):198-9. PubMed ID: 24702
    [No Abstract]   [Full Text] [Related]  

  • 9. [The purification of dialysate].
    Urano H; Suzuki M; Hirasawa Y
    Nihon Rinsho; 1991 Dec; 49 Suppl():307-13. PubMed ID: 1808274
    [No Abstract]   [Full Text] [Related]  

  • 10. Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration.
    Maerz H; Hahn SO; Maassen A; Meisel H; Roggenbuck D; Sato T; Tanzmann H; Emmrich F; Marx U
    Nat Biotechnol; 1996 May; 14(5):651-2. PubMed ID: 9630961
    [No Abstract]   [Full Text] [Related]  

  • 11. Educational program to reduce major bleeding in patients undergoing percutaneous coronary interventions and receiving abciximab.
    Dobesh PP; Lakamp JE
    Am J Health Syst Pharm; 2002 Aug; 59(16):1539-42. PubMed ID: 12185830
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hydrophobic membranes and membranes with positive electric charges: new prospects for removal of pyrogens from solutions?].
    Carazzone M; Fava M; Modesto A
    Boll Chim Farm; 1986 Feb; 125(2):43-51. PubMed ID: 3741643
    [No Abstract]   [Full Text] [Related]  

  • 13. [Abciximab].
    Yokoyama K; Ikeda Y
    Nihon Rinsho; 2006 Oct; 64 Suppl 7():627-9. PubMed ID: 17465067
    [No Abstract]   [Full Text] [Related]  

  • 14. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting.
    Kopp CW; Steiner S; Nasel C; Seidinger D; Mlekusch I; Lang W; Bartok A; Ahmadi R; Minar E
    Stroke; 2003 Nov; 34(11):2560-7. PubMed ID: 14563968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methods for ensuring the apyrogenic quality of injection solutions in hospital pharmacies].
    Eroshevskiĭ AA; Khveshchuk PF; Riabykh LD
    Voen Med Zh; 1991 Mar; (3):59-60. PubMed ID: 1853599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification of antibody Fab and F(ab')2 fragments using Gradiflow technology.
    Cheung GL; Thomas TM; Rylatt DB
    Protein Expr Purif; 2003 Nov; 32(1):135-40. PubMed ID: 14680950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystallization and preliminary X-ray diffraction studies of complexes between an influenza hemagglutinin and Fab fragments of two different monoclonal antibodies.
    Gigant B; Fleury D; Bizebard T; Skehel JJ; Knossow M
    Proteins; 1995 Sep; 23(1):115-7. PubMed ID: 8539243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary stenting and use of abciximab.
    Mohl W; Menges M; Hennen B; Schieffer H; Zeitz M
    Lancet; 1998 Oct; 352(9136):1312. PubMed ID: 9788485
    [No Abstract]   [Full Text] [Related]  

  • 19. MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window.
    Mandava P; Anderson JA; Kent TA
    Neurology; 2006 Apr; 66(7):1132. PubMed ID: 16606946
    [No Abstract]   [Full Text] [Related]  

  • 20. Coronary stenting and use of abciximab.
    Alvarez JM
    Lancet; 1998 Oct; 352(9136):1311-2. PubMed ID: 9788484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.